Health Care • Biotechnology: Pharmaceutical Preparations
$27.62 ▼ -0.77
(-2.71%)
MKT CAP: $1.85B • VOL: 408.3K
52W L $14 52W H $45
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$23
MEDIAN
$31
MEAN
$31
HIGH
$38
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ZBIO TAPE
ZBIO // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $33.42 | $31.76 | 2025-02-14 | $25.13 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $34.80 | $32.59 | 2025-02-06 | $25.96 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $31.49 | $30.38 | 2025-01-29 | $26.52 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $28.17 | — | 2025-01-17 | $27.07 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $24.31 | $26.24 | 2025-01-09 | $24.58 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $32.87 | $28.72 | 2024-12-18 | $24.03 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $26.79 | $27.90 | 2024-12-04 | $25.69 | -4.3% | 48% | C |